Comparing the Effect of Early Versus Delayed Metformin Treatment on Glycaemic Parameters Among Australian Adults With Incident Diabetes: Evidence Using a National General Practice Database
Clin Ther. 2024 Apr 1:S0149-2918(24)00067-5. doi: 10.1016/j.clinthera.2024.03.001. Online ahead of print.ABSTRACTPURPOSE: To compare the effect of early vs delayed metformin treatment for glycaemic management among patients with incident diabetes.METHODS: Cohort study using electronic health records of regular patients (1+ visits per year in 3 consecutive years) aged 40+ years with 'incident' diabetes attending Australian general practices (MedicineInsight, 2011-2018). Patients with incident diabetes were defined as those who had a) 12+ months of medical data before the first recording of a diabetes diagnosis AND b) a diag...
Source: Clinical Therapeutics - April 2, 2024 Category: Drugs & Pharmacology Authors: Mingyue Zheng Mumtaz Begum Carla De Oliveira Bernardo Nigel Stocks David Gonzalez-Chica Source Type: research
Comparison of Cefazolin and Ceftriaxone Enterobacterales Susceptibilities for Inpatient Treatment of Urinary Tract Infections and Risk of Hospital-Onset Clostridioides difficile Infection
Clin Ther. 2024 Mar 28:S0149-2918(24)00066-3. doi: 10.1016/j.clinthera.2024.02.011. Online ahead of print.ABSTRACTPURPOSE: Urinary tract infection (UTI) is the second most common indication for antibiotic therapy among inpatients in the United States. Ceftriaxone, a third-generation cephalosporin, is habitually chosen to treat inpatient UTIs due to familiarity, cost, and perceived safety. However, third-generation cephalosporins increase the risk of health care facility-onset Clostridioides difficile infection (HOCDI) more than any other antibiotic group, while no statistical risk exists for first-generation cephalosporins...
Source: Clinical Therapeutics - March 29, 2024 Category: Drugs & Pharmacology Authors: Eric Wombwell Allison Rosa Source Type: research
The Pharmacogenetic Variability Associated With the Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Healthy Chinese Subjects: A National Multicenter Exploratory Study
This study aimed to explore the pharmacogenetic variability associated with the pharmacokinetics (PK) and pharmacodynamics (PD) of rivaroxaban in healthy Chinese subjects.METHODS: This was a multicenter study that included 304 healthy adults aged 18 to 45 years with unknown genotypes. All participants were administered a single dose of rivaroxaban at 10 mg, 15 mg, or 20 mg. PK and PD parameters were measured, and exome-wide association analysis was conducted.FINDINGS: Sixteen SNPs located on 11 genes influenced the AUC0-t. Among these, the 3 most influential genes were MiR516A2, PARP14, and MIR618. Thirty-six SNPs from 28 ...
Source: Clinical Therapeutics - March 29, 2024 Category: Drugs & Pharmacology Authors: Zhiyan Liu Qiufen Xie Xia Zhao Yunlong Tan Wenping Wang Yu Cao Xiaohua Wei Guangyan Mu Hanxu Zhang Shuang Zhou Xiaobin Wang Ying Cao Xin Li Song Chen Duanwen Cao Yimin Cui Qian Xiang Source Type: research
Comparison of Cefazolin and Ceftriaxone Enterobacterales Susceptibilities for Inpatient Treatment of Urinary Tract Infections and Risk of Hospital-Onset Clostridioides difficile Infection
Clin Ther. 2024 Mar 28:S0149-2918(24)00066-3. doi: 10.1016/j.clinthera.2024.02.011. Online ahead of print.ABSTRACTPURPOSE: Urinary tract infection (UTI) is the second most common indication for antibiotic therapy among inpatients in the United States. Ceftriaxone, a third-generation cephalosporin, is habitually chosen to treat inpatient UTIs due to familiarity, cost, and perceived safety. However, third-generation cephalosporins increase the risk of health care facility-onset Clostridioides difficile infection (HOCDI) more than any other antibiotic group, while no statistical risk exists for first-generation cephalosporins...
Source: Clinical Therapeutics - March 29, 2024 Category: Drugs & Pharmacology Authors: Eric Wombwell Allison Rosa Source Type: research
The Pharmacogenetic Variability Associated With the Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Healthy Chinese Subjects: A National Multicenter Exploratory Study
This study aimed to explore the pharmacogenetic variability associated with the pharmacokinetics (PK) and pharmacodynamics (PD) of rivaroxaban in healthy Chinese subjects.METHODS: This was a multicenter study that included 304 healthy adults aged 18 to 45 years with unknown genotypes. All participants were administered a single dose of rivaroxaban at 10 mg, 15 mg, or 20 mg. PK and PD parameters were measured, and exome-wide association analysis was conducted.FINDINGS: Sixteen SNPs located on 11 genes influenced the AUC0-t. Among these, the 3 most influential genes were MiR516A2, PARP14, and MIR618. Thirty-six SNPs from 28 ...
Source: Clinical Therapeutics - March 29, 2024 Category: Drugs & Pharmacology Authors: Zhiyan Liu Qiufen Xie Xia Zhao Yunlong Tan Wenping Wang Yu Cao Xiaohua Wei Guangyan Mu Hanxu Zhang Shuang Zhou Xiaobin Wang Ying Cao Xin Li Song Chen Duanwen Cao Yimin Cui Qian Xiang Source Type: research
Comparison of Cefazolin and Ceftriaxone Enterobacterales Susceptibilities for Inpatient Treatment of Urinary Tract Infections and Risk of Hospital-Onset Clostridioides difficile Infection
Clin Ther. 2024 Mar 28:S0149-2918(24)00066-3. doi: 10.1016/j.clinthera.2024.02.011. Online ahead of print.ABSTRACTPURPOSE: Urinary tract infection (UTI) is the second most common indication for antibiotic therapy among inpatients in the United States. Ceftriaxone, a third-generation cephalosporin, is habitually chosen to treat inpatient UTIs due to familiarity, cost, and perceived safety. However, third-generation cephalosporins increase the risk of health care facility-onset Clostridioides difficile infection (HOCDI) more than any other antibiotic group, while no statistical risk exists for first-generation cephalosporins...
Source: Clinical Therapeutics - March 29, 2024 Category: Drugs & Pharmacology Authors: Eric Wombwell Allison Rosa Source Type: research
The Pharmacogenetic Variability Associated With the Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Healthy Chinese Subjects: A National Multicenter Exploratory Study
This study aimed to explore the pharmacogenetic variability associated with the pharmacokinetics (PK) and pharmacodynamics (PD) of rivaroxaban in healthy Chinese subjects.METHODS: This was a multicenter study that included 304 healthy adults aged 18 to 45 years with unknown genotypes. All participants were administered a single dose of rivaroxaban at 10 mg, 15 mg, or 20 mg. PK and PD parameters were measured, and exome-wide association analysis was conducted.FINDINGS: Sixteen SNPs located on 11 genes influenced the AUC0-t. Among these, the 3 most influential genes were MiR516A2, PARP14, and MIR618. Thirty-six SNPs from 28 ...
Source: Clinical Therapeutics - March 29, 2024 Category: Drugs & Pharmacology Authors: Zhiyan Liu Qiufen Xie Xia Zhao Yunlong Tan Wenping Wang Yu Cao Xiaohua Wei Guangyan Mu Hanxu Zhang Shuang Zhou Xiaobin Wang Ying Cao Xin Li Song Chen Duanwen Cao Yimin Cui Qian Xiang Source Type: research
Comparison of Cefazolin and Ceftriaxone Enterobacterales Susceptibilities for Inpatient Treatment of Urinary Tract Infections and Risk of Hospital-Onset Clostridioides difficile Infection
Clin Ther. 2024 Mar 28:S0149-2918(24)00066-3. doi: 10.1016/j.clinthera.2024.02.011. Online ahead of print.ABSTRACTPURPOSE: Urinary tract infection (UTI) is the second most common indication for antibiotic therapy among inpatients in the United States. Ceftriaxone, a third-generation cephalosporin, is habitually chosen to treat inpatient UTIs due to familiarity, cost, and perceived safety. However, third-generation cephalosporins increase the risk of health care facility-onset Clostridioides difficile infection (HOCDI) more than any other antibiotic group, while no statistical risk exists for first-generation cephalosporins...
Source: Clinical Therapeutics - March 29, 2024 Category: Drugs & Pharmacology Authors: Eric Wombwell Allison Rosa Source Type: research
The Pharmacogenetic Variability Associated With the Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Healthy Chinese Subjects: A National Multicenter Exploratory Study
This study aimed to explore the pharmacogenetic variability associated with the pharmacokinetics (PK) and pharmacodynamics (PD) of rivaroxaban in healthy Chinese subjects.METHODS: This was a multicenter study that included 304 healthy adults aged 18 to 45 years with unknown genotypes. All participants were administered a single dose of rivaroxaban at 10 mg, 15 mg, or 20 mg. PK and PD parameters were measured, and exome-wide association analysis was conducted.FINDINGS: Sixteen SNPs located on 11 genes influenced the AUC0-t. Among these, the 3 most influential genes were MiR516A2, PARP14, and MIR618. Thirty-six SNPs from 28 ...
Source: Clinical Therapeutics - March 29, 2024 Category: Drugs & Pharmacology Authors: Zhiyan Liu Qiufen Xie Xia Zhao Yunlong Tan Wenping Wang Yu Cao Xiaohua Wei Guangyan Mu Hanxu Zhang Shuang Zhou Xiaobin Wang Ying Cao Xin Li Song Chen Duanwen Cao Yimin Cui Qian Xiang Source Type: research
Commentary on Hey, Hunter, Muller et al. A Never-Ending Story: Evaluating Evidence in Medicinal Product Decision Making
Clin Ther. 2024 Mar 22:S0149-2918(24)00039-0. doi: 10.1016/j.clinthera.2024.02.001. Online ahead of print.NO ABSTRACTPMID:38521732 | DOI:10.1016/j.clinthera.2024.02.001 (Source: Clinical Therapeutics)
Source: Clinical Therapeutics - March 23, 2024 Category: Drugs & Pharmacology Authors: Steven Hirschfeld Source Type: research
Commentary on Hey, Hunter, Muller et al. A Never-Ending Story: Evaluating Evidence in Medicinal Product Decision Making
Clin Ther. 2024 Mar 22:S0149-2918(24)00039-0. doi: 10.1016/j.clinthera.2024.02.001. Online ahead of print.NO ABSTRACTPMID:38521732 | DOI:10.1016/j.clinthera.2024.02.001 (Source: Clinical Therapeutics)
Source: Clinical Therapeutics - March 23, 2024 Category: Drugs & Pharmacology Authors: Steven Hirschfeld Source Type: research
Commentary on Hey, Hunter, Muller et al. A Never-Ending Story: Evaluating Evidence in Medicinal Product Decision Making
Clin Ther. 2024 Mar 22:S0149-2918(24)00039-0. doi: 10.1016/j.clinthera.2024.02.001. Online ahead of print.NO ABSTRACTPMID:38521732 | DOI:10.1016/j.clinthera.2024.02.001 (Source: Clinical Therapeutics)
Source: Clinical Therapeutics - March 23, 2024 Category: Drugs & Pharmacology Authors: Steven Hirschfeld Source Type: research
Commentary on Hey, Hunter, Muller et al. A Never-Ending Story: Evaluating Evidence in Medicinal Product Decision Making
Clin Ther. 2024 Mar 22:S0149-2918(24)00039-0. doi: 10.1016/j.clinthera.2024.02.001. Online ahead of print.NO ABSTRACTPMID:38521732 | DOI:10.1016/j.clinthera.2024.02.001 (Source: Clinical Therapeutics)
Source: Clinical Therapeutics - March 23, 2024 Category: Drugs & Pharmacology Authors: Steven Hirschfeld Source Type: research
Commentary on Hey, Hunter, Muller et al. A Never-Ending Story: Evaluating Evidence in Medicinal Product Decision Making
Clin Ther. 2024 Mar 22:S0149-2918(24)00039-0. doi: 10.1016/j.clinthera.2024.02.001. Online ahead of print.NO ABSTRACTPMID:38521732 | DOI:10.1016/j.clinthera.2024.02.001 (Source: Clinical Therapeutics)
Source: Clinical Therapeutics - March 23, 2024 Category: Drugs & Pharmacology Authors: Steven Hirschfeld Source Type: research
Explainable and Interpretable Machine Learning for Antimicrobial Stewardship: Opportunities and Challenges
Clin Ther. 2024 Mar 21:S0149-2918(24)00065-1. doi: 10.1016/j.clinthera.2024.02.010. Online ahead of print.ABSTRACTThere is growing interest in exploiting the advances in artificial intelligence and machine learning (ML) for improving and monitoring antimicrobial prescriptions in line with antimicrobial stewardship principles. Against this background, the concepts of interpretability and explainability are becoming increasingly essential to understanding how ML algorithms could predict antimicrobial resistance or recommend specific therapeutic agents, to avoid unintended biases related to the "black box" nature of complex m...
Source: Clinical Therapeutics - March 22, 2024 Category: Drugs & Pharmacology Authors: Daniele Roberto Giacobbe Cristina Marelli Sabrina Guastavino Sara Mora Nicola Rosso Alessio Signori Cristina Campi Mauro Giacomini Matteo Bassetti Source Type: research
